Isolation and structure elucidation of photodegradation products of fexofenadine
The photostability of the antihistamine fexofenadine hydrochloride is described. The stress studies revealed the photostability of the drug as the most adverse stability factor. The main photodegradation products were isolated and its structures were elucidated by 1H, 13C, COSY, HSQC, HMBC NMR and m...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
2008
|
| Materias: | |
| Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 08850caa a22012497a 4500 | ||
|---|---|---|---|
| 001 | PAPER-22471 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518205402.0 | ||
| 008 | 190411s2008 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-37749020310 | |
| 024 | 7 | |2 cas |a benzophenone, 119-61-9; croscarmellose sodium, 74811-65-7; fexofenadine, 138452-21-8; hydroxypropylmethylcellulose, 9004-65-3; iron oxide, 1332-37-2; macrogol, 25322-68-3; magnesium stearate, 557-04-0; microcrystalline cellulose, 39394-43-9, 51395-75-6; povidone, 9003-39-8; silicon dioxide, 10279-57-9, 14464-46-1, 14808-60-7, 15468-32-3, 60676-86-0, 7631-86-9; starch, 9005-25-8, 9005-84-9; titanium dioxide, 1317-70-0, 1317-80-2, 13463-67-7, 51745-87-0; fexofenadine, 138452-21-8; Histamine H1 Antagonists; Terfenadine, 50679-08-8 | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 030 | |a JPBAD | ||
| 100 | 1 | |a Breier, A.R. | |
| 245 | 1 | 0 | |a Isolation and structure elucidation of photodegradation products of fexofenadine |
| 260 | |c 2008 | ||
| 270 | 1 | 0 | |m Breier, A.R.; Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Av. Ipiranga, 2752, Porto Alegre, RS CEP 90610-000, Brazil; email: anarita_breier@hotmail.com |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a Simpson, K., Jarvis, B., (2000) Drugs, 59, pp. 301-321 | ||
| 504 | |a Markham, A., Wagstaff, A.J., (1998) Drugs, 55, pp. 269-274 | ||
| 504 | |a Amichai, B., Grunwald, M.H., Brenner, L., (2001) Isr. Med. Assoc. J., 3, pp. 207-209 | ||
| 504 | |a Estelle, F., Simons, R., (2002) Allergy. 2 ed., pp. 834-863. , Kaplan A.P. (Ed), W.B. Saunders Company, Philadelphia | ||
| 504 | |a Borade, P.S., Ballary, C.C., Currie, G.P., Lee, D.K.S., (2006) Drug Discov. Today: Ther. Strateg., 3, pp. 253-259 | ||
| 504 | |a Kawashima, M., Harada, S., (2007) J. Dermatol., 34, pp. 9-16 | ||
| 504 | |a Howarth, P.H., (2002) Clin. Exp. Allergy, 2, pp. 18-25 | ||
| 504 | |a Hofmann, U., Seiler, M., Drescher, S., Fromm, M.F., (2002) J. Chromatogr. B, 766, pp. 227-233 | ||
| 504 | |a Gergov, M., Robson, J.N., Ojanperä, I., Heinonen, O.P., Vuori, E., (2001) Forensic Sci. Int., 121, pp. 108-115 | ||
| 504 | |a Fu, I., Woolf, E.J., Matuszewski, B.K., (2004) J. Pharm. Biomed. Anal., 35, pp. 837-846 | ||
| 504 | |a Nirogi, R.V., Kandikere, V.N., Shukla, M., Mudigonda, K., Maurya, S., Komarneni, P., (2007) Biomed. Chromatogr., 21, pp. 209-216 | ||
| 504 | |a Uno, T., Yasui-Furukori, N., Takahata, T., Sugawara, K., Tateishi, T., (2004) J. Pharm. Biomed. Anal., 35, pp. 937-942 | ||
| 504 | |a Miura, M., Uno, T., Tateishi, T., Suzuki, T., (2007) J. Pharm. Biomed. Anal., 43, pp. 741-745 | ||
| 504 | |a Gazy, A.A., Mahgoub, H., El-Yazbi, F.A., El-Sayed, M.A., Youssef, R.M., (2002) J. Pharm. Biomed. Anal., 30, pp. 859-867 | ||
| 504 | |a Radhakrishna, T., Reddy, G.O., (2002) J. Pharm. Biomed. Anal., 24, pp. 755-767 | ||
| 504 | |a Breier, A.R., Menegola, J., Paim, C.S., Steppe, M., Schapoval, E.E.S., (2004) J. AOAC Int., 87, pp. 1093-1097 | ||
| 504 | |a Breier, A.R., Garcia, S.S., Jablonski, A., Steppe, M., Schapoval, E.E.S., (2005) J. AOAC Int., 88, pp. 1059-1063 | ||
| 504 | |a Mikus, P., Valásková, I., Havránek, E., (2005) Drug Dev. Ind. Pharm., 31, pp. 795-801 | ||
| 504 | |a Breier, A.R., Paim, C.S., Steppe, M., Schapoval, E.E.S., (2005) J. Pharm. Pharm. Sci., 8, pp. 289-298 | ||
| 504 | |a Walker, T.A., Schmitt, G.L., (2006) J. Liquid Chromatogr. Relat. Technol., 2, pp. 25-43 | ||
| 504 | |a Valvini, S.C., (2000) Drug stability, Principles and Practices. 3rd ed., pp. 515-552. , Carstensen J.T., and Rhodes C.T. (Eds), Marcel Dekker, New York | ||
| 504 | |a Breier, A.R., Steppe, M., Schapoval, E.E.S., (2006) Chromatographia, 64, pp. 725-729 | ||
| 504 | |a Nudelman, N.S., Cabrera, C.G., (2002) J. Pharm. Sci., 91, pp. 1274-1285 | ||
| 504 | |a Tonnesen, H.H., (1996) Photostability of Drugs and Drug Formulations, pp. 1-7. , Tonnesen H.H. (Ed), Taylor & Francis, London | ||
| 504 | |a Kommanaboyina, B., Rhodes, C.T., (1999) Drug Dev. Ind. Pharm., 25, pp. 857-868 | ||
| 504 | |a Tonnesen, H.H., (2001) Int. J. Pharm., 225, pp. 1-14 | ||
| 504 | |a Moore, D.E., (1996) Photostability of Drugs and Drug Formulations, pp. 63-82. , Tonnesen H.H. (Ed), Taylor & Francis, London | ||
| 504 | |a Pretsch, E., Bühlmann, P., Affolter, C., (2000) Structure Determination of Organic Compounds, , Springer, New York pp. 1-243 | ||
| 504 | |a Breitmaier, E., (1993) Structure Elucidation by NMR in Organic Chemistry: A Practical Guide, , John Wiley & Sons, Chichester pp. 71-259 | ||
| 504 | |a (2004) Clarke's Analysis of Drugs and Poisons in Pharmaceuticals, Body Fluids and Postmortem Material, pp. 1033-1034. , Moffat A.C. (Ed), Pharmaceutical Press, London | ||
| 520 | 3 | |a The photostability of the antihistamine fexofenadine hydrochloride is described. The stress studies revealed the photostability of the drug as the most adverse stability factor. The main photodegradation products were isolated and its structures were elucidated by 1H, 13C, COSY, HSQC, HMBC NMR and mass spectrometry techniques. The drug was exposed to UVC light at 254 nm in methanolic solutions and the degradation was followed by HPLC and TLC. The photostability of fexofenadine tablets was studied and the same degradation products were observed. The two photodegradation products isolated were characterized as the isopropyl derivative, obtained by decarboxilation of fexofenadine, and a benzophenone compound, which was obtained by rearrangement of aromatic rings and oxidation reactions. The results show the importance of appropriate light protection during the drug development process, storage and handling. © 2007 Elsevier B.V. All rights reserved. |l eng | |
| 536 | |a Detalles de la financiación: Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq | ||
| 536 | |a Detalles de la financiación: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior | ||
| 536 | |a Detalles de la financiación: The authors thank to LEPCQ, CNPq and CAPES for the financial support. | ||
| 593 | |a Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Av. Ipiranga, 2752, Porto Alegre, RS CEP 90610-000, Brazil | ||
| 593 | |a Facultad de Ciencias Exactas, Universidad de Buenos Aires, Pab. II P.3, Ciudad Universitaria, 1428EHA Buenos Aires, Argentina | ||
| 690 | 1 | 0 | |a FEXOFENADINE HYDROCHLORIDE |
| 690 | 1 | 0 | |a FEXOFENADINE PHOTODEGRADATION PRODUCTS |
| 690 | 1 | 0 | |a FEXOFENADINE PHOTOSTABILITY |
| 690 | 1 | 0 | |a PHOTODEGRADATION |
| 690 | 1 | 0 | |a QUALITY CONTROL |
| 690 | 1 | 0 | |a AROMATIC COMPOUND |
| 690 | 1 | 0 | |a BENZOPHENONE |
| 690 | 1 | 0 | |a CROSCARMELLOSE SODIUM |
| 690 | 1 | 0 | |a EXCIPIENT |
| 690 | 1 | 0 | |a FEXOFENADINE |
| 690 | 1 | 0 | |a HYDROXYPROPYLMETHYLCELLULOSE |
| 690 | 1 | 0 | |a IRON OXIDE |
| 690 | 1 | 0 | |a MACROGOL |
| 690 | 1 | 0 | |a MAGNESIUM STEARATE |
| 690 | 1 | 0 | |a MICROCRYSTALLINE CELLULOSE |
| 690 | 1 | 0 | |a POVIDONE |
| 690 | 1 | 0 | |a SILICON DIOXIDE |
| 690 | 1 | 0 | |a STARCH |
| 690 | 1 | 0 | |a TITANIUM DIOXIDE |
| 690 | 1 | 0 | |a ARTICLE |
| 690 | 1 | 0 | |a CARBON NUCLEAR MAGNETIC RESONANCE |
| 690 | 1 | 0 | |a DECARBOXYLATION |
| 690 | 1 | 0 | |a DRUG ISOLATION |
| 690 | 1 | 0 | |a DRUG STABILITY |
| 690 | 1 | 0 | |a DRUG STORAGE |
| 690 | 1 | 0 | |a DRUG STRUCTURE |
| 690 | 1 | 0 | |a HETERONUCLEAR MULTIPLE BOND CORRELATION |
| 690 | 1 | 0 | |a HETERONUCLEAR SINGLE QUANTUM COHERENCE |
| 690 | 1 | 0 | |a HIGH PERFORMANCE LIQUID CHROMATOGRAPHY |
| 690 | 1 | 0 | |a OXIDATION |
| 690 | 1 | 0 | |a PHOTODEGRADATION |
| 690 | 1 | 0 | |a PRIORITY JOURNAL |
| 690 | 1 | 0 | |a PROTON NUCLEAR MAGNETIC RESONANCE |
| 690 | 1 | 0 | |a QUALITY CONTROL |
| 690 | 1 | 0 | |a STRESS |
| 690 | 1 | 0 | |a THIN LAYER CHROMATOGRAPHY |
| 690 | 1 | 0 | |a HISTAMINE H1 ANTAGONISTS |
| 690 | 1 | 0 | |a MOLECULAR STRUCTURE |
| 690 | 1 | 0 | |a PHOTOCHEMISTRY |
| 690 | 1 | 0 | |a SPECTROPHOTOMETRY, ULTRAVIOLET |
| 690 | 1 | 0 | |a TERFENADINE |
| 653 | 0 | 0 | |a allegra |
| 700 | 1 | |a Nudelman, N.S. | |
| 700 | 1 | |a Steppe, M. | |
| 700 | 1 | |a Schapoval, E.E.S. | |
| 773 | 0 | |d 2008 |g v. 46 |h pp. 250-257 |k n. 2 |p J. Pharm. Biomed. Anal. |x 07317085 |w (AR-BaUEN)CENRE-5736 |t Journal of Pharmaceutical and Biomedical Analysis | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-37749020310&doi=10.1016%2fj.jpba.2007.09.017&partnerID=40&md5=b07e66b95eb9326784e0a5c872aeff2b |y Registro en Scopus |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jpba.2007.09.017 |y DOI |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_07317085_v46_n2_p250_Breier |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_07317085_v46_n2_p250_Breier |y Registro en la Biblioteca Digital |
| 961 | |a paper_07317085_v46_n2_p250_Breier |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 83424 | ||